Heat shock protein gp96 adjuvant induces T cell responses and cross-protection to a split influenza vaccine
0301 basic medicine
Immunity, Cellular
Mice, Inbred BALB C
0303 health sciences
Cross Protection
CD8-Positive T-Lymphocytes
Hemagglutination Inhibition Tests
Antibodies, Viral
Immunity, Humoral
3. Good health
03 medical and health sciences
Influenza A Virus, H1N1 Subtype
Adjuvants, Immunologic
Orthomyxoviridae Infections
Influenza Vaccines
Neutralization Tests
Animals
Female
Heat-Shock Proteins
DOI:
10.1016/j.vaccine.2014.03.045
Publication Date:
2014-04-01T06:54:22Z
AUTHORS (10)
ABSTRACT
The commonly used inactivated or split influenza vaccines induce only induce minimal T cell responses and are less effective in preventing heterologous virus infection. Thus, developing cross-protective influenza vaccines against the spread of a new influenza virus is an important strategy against pandemic emergence. Here we demonstrated that immunization with heat shock protein gp96 as adjuvant led to a dramatic increased antigen-specific T cell response to a pandemic H1N1 split vaccine. Notably, gp96 elicited a cross-protective CD8(+) T cell response to the internal conserved viral protein NP. Although the split pH1N1vaccine alone has low cross-protective efficiency, adding gp96 as an adjuvant effectively improved the cross-protection against challenge with a heterologous virus in mice. Our study reveals the novel property of gp96 in boosting the T cell response against conserved epitopes of influenza virus and its potential use as an adjuvant for human pre-pandemic inactivated influenza vaccines against different viral subtypes.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (52)
CITATIONS (21)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....